Neogenomics (NEO) Capital Expenditures (2010 - 2026)

Neogenomics (NEO) has reported Capital Expenditures for 17 consecutive years, with $5.0 million the latest figure, recorded in Q1 2026.

• Capital Expenditures for Q1 2026 came in at $5.0 million, up 11.11% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.2 million (up 3132.88% YoY), and the FY2025 annual result was $1.7 million, up 69.37% from the prior year.
• Capital Expenditures was $5.0 million for Q1 2026 at Neogenomics, up from -$17.4 million in the prior quarter.
• Over five years, Capital Expenditures peaked at $16.2 million in Q2 2023 and troughed at -$28.4 million in Q4 2024.
• Average Capital Expenditures over 5 years is $589647.1, with a median of $5.6 million recorded in 2024.
• The widest YoY moves for Capital Expenditures: up 375.72% in 2024, down 109323.08% in 2024.
• Over 5 years, Capital Expenditures stood at -$24.7 million in 2022, then surged by 99.89% to -$26000.0 in 2023, then tumbled by 109323.08% to -$28.4 million in 2024, then jumped by 38.76% to -$17.4 million in 2025, then jumped by 128.7% to $5.0 million in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $5.0 million in Q1 2026, -$17.4 million in Q4 2025, and $8.3 million in Q3 2025.